Deals
Blackstone Buys Japan Drug Trial Firm, Adding to PE Health Deals
- Tokyo-based CMIC is valued at hundreds of millions of dollars
- Attracted by Japan’s efforts to speed up drug approvals
This article is for subscribers only.
Blackstone Inc. is buying a company that helps drugmakers run clinical trials in Japan, adding to growing interest from private equity firms in the health needs of the nation’s aging population.
The world’s largest alternative asset manager said it agreed to purchase 60% of Tokyo-based CMIC Co., a contract research organization, in a deal that values the company in the hundreds of millions of dollars.